Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
In a retrospective analysis, researchers investigated whether patients with hypertension who received ACEIs/ARBs experienced heightened complications of the illness or were at a greater risk of mortality during COVID-19 infection.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Angiotensin-converting enzyme 2 (ACE2)
Biomedical Sciences
Related
Factors that can potentially increase ACE2 expression in the Cardiovascular System
Inhibitors of the Renin–Angiotensin–Aldosterone System (RAAS) and COVID-19
Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Troponin and cardiovascular disease in relation to COVID-19
Learn After
Discussion of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Results of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)
Stats for COVID-19 Patients with Hypertension (needs date of study)